The previously described [16, 22–25, 31, 32, 52–56, 68–71] wide level expression of CEA, brachyury, and MUC1 in a range of human carcinomas, along with their diverse activity in human tumors, renders the simultaneous targeting of these three TAAs of potential clinical benefit. This evidence concerns the gene MUC1 and carcinoma.